Earnings Releases·Nov 10, 2026, 4:43 PM ET

KORU Medical Systems — Third Quarter 2026 Earnings Summary

Net revenues increased 11.2% year-over-year to $11.6 million for the quarter, with year-to-date growth of 17% to $35.4 million; net income turned positive at $0.2 million compared to a $0.8 million loss in the prior year period.
Full-year 2026 revenue guidance was revised upward to $48.0–$48.5 million and gross margin guidance raised to 63%–64%, while adjusted EBITDA guidance remains positive and year-end cash balance guidance increased to over $8.0 million.
Domestic Core revenues grew 31.6% to $8.1 million, offset by declines in International Core (down 16.5%) and Pharma Services (down 27.4%) segments due to timing of distributor inventory and specific customer program reductions.
Management anticipates revenue reacceleration in Q4 following the completion of a competitive non-tender market entry in Europe, supported by two new sales agreements in Europe and Africa and the acquisition of a technology asset.